Could high levels of tissue polypeptide specific antigen, a marker of apoptosis detected in nonalcoholic steatohepatitis, improve after weight loss?

Disease Markers

Volumn 26, Issue 2, 2009, Pages 55-63

  Tarantino, Giovanni ^a   Mazzarella, Claudia ^a   Tarantino, Marianna ^a   Di Minno, Matteo Nicola Dario ^a   Conca, Paolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Body Weight loss; NASH; TPS

Indexed keywords

ALANINE AMINOTRANSFERASE; TISSUE POLYPEPTIDE ANTIGEN; BIOLOGICAL MARKER; PEPTIDE; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN;

APOPTOSIS; ARTICLE; BODY MASS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION; AGED; ANTHROPOMETRY; BLOOD; CALORIC RESTRICTION; CROSS-SECTIONAL STUDY; FATTY LIVER; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY;

AGED; ALANINE TRANSAMINASE; ANTHROPOMETRY; APOPTOSIS; BIOLOGICAL MARKERS; BODY MASS INDEX; CALORIC RESTRICTION; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PEPTIDES; PILOT PROJECTS; WEIGHT LOSS;

EID: 67449088337     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/292458     Document Type: Article

References (31)

1. D.A. Lawlor, C.L. Hart, D.J. Hole and S.G. Davey, Reverse causality and confounding and the associations of overweight and obesity with mortality, Obesity 14 (2006), 2294-304.
2. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu and A.J. McCullough, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology 116 (1999), 1413-1419.
3. M. Machado, P. Marques-Vidal and H. Cortez-Pinto, Hepatic histology in obese patients undergoing bariatric surgery, J Hepatol 45 (2006), 600-606.
4. P. Colicchio, G. Tarantino, F. del Genio, P. Sorrentino, G. Saldalamacchia, C. Finelli et al., Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy, Ann Nutr Metab 49 (2005), 289-295.
5. C.E. Ruhl and J.E. Everhart, Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States, Gastroenterology 124 (2003), 71-79.
6. F.H. Luyckx, P.J. Lefebvre and A.J. Scheen, Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss, Diabetes Metab 26 (2000), 98-106.
7. M. Okita, M. Hayashi, T. Sasagawa, K. Takagi, K. Suzuki, S. Kinoyama et al., Effect of a moderately energy-restricted diet on obese patients with fatty liver, Nutrition 17 (2001), 542-547.
8. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri and B.R. Bacon, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol 94 (1999), 2467-2474.
9. A. Wieckowska, N.N. Zein, L.M. Yerian, A.R. Lopez, A.J. McCullough and A.E. Feldstein, In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease, Hepatology 44 (2006), 27-33.
10. Y. Yilmaz, E. Dolar, E. Ulukaya, S. Akgoz, M. Keskin, M. Kiyici et al., Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis, World J Gastroenterol 13 (2007), 837-844.
11. G. Tarantino, P. Conca, A. Coppola, R. Vecchione and G. Di Minno, Serum concentrations of the tissue polypeptide specific antigen in patients suffering from non-alcoholic steatohepatitis, Eur J Clin Invest 37 (2007), 48-53.
12. M.A. Sheard, B. Vojtesek, M. Simickova and D.Valik, Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis, J Cell Biochem 85 (2002), 670-677.
13. B. Schutte, M. Henfling, W. Kolgen, M. Bouman, S. Meex, M.P. Leers et al., Keratin 8/18 breakdown and reorganization during apoptosis, Exp Cell Res 297 (2004), 11-26.
14. A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, K.D. Lindor et al., Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis, Gastroenterology 125 (2003), 437-443.
15. I.J. Hickman, J.R. Jonsson, J.B. Prins, S. Ash, D.M. Purdie, A.D. Clouston et al., Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life, Gut 53 (2004), 413-419.
16. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, B.A. Franklin et al., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation 112 (2005), 2735-2752.
17. U.L. Mathiesen, L.E. Franzen, H. Aselius, M. Resjo, L. Jacobsson, U. Foberg et al., Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases, Dig Liver Dis 34 (2002), 516-522.
18. R.Rocha, H.P. Cotrim, F.M. Carvalho, A.C. Siqueira, H.Braga and L.A. Freitas, Body mass index and waist circumference in non-alcoholic fatty liver disease, J Hum Nutr Diet 18 (2005), 365-370.
19. F. Nothwehr, L. Snetselaar and H. Wu, Weight management strategies reported by rural men and women in Iowa, J Nutr Educ Behav 38 (2006), 249-253.
20. V. Ratziu, F. Charlotte, A. Heurtier, S. Gombert, P. Giral, E. Bruckert et al., Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology 128 (2005), 1898-1906.
21. M.A. Huang, J.K. Greenson, C. Chao, L. Anderson, D. Peterman, J. Jacobson et al., One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study, Am J Gastroenterol 100 (2005), 1072-1081.
22. A.O. Rantala, M.Lilja, H. Kauma, M.J. Savolainen, A. Reunanen and Y.A. Kesaniemi, Gamma-glutamyl transpeptidase and the metabolic syndrome, J Intern Med 248 (2000), 230-238.
23. P. Sorrentino, G. Tarantino, A. Perrella, P. Micheli, O. Perrella and P. Conca, A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease, Dig Dis Sci 50 (2005), 1130-1135.
24. A. Suzuki, P. Angulo, J. Lymp, D. Li, S. Satomura and K. Lindor, Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease, Liver Int 25 (2005), 779-786.
25. R. Morra, M. Munteanu, P. Bedossa, D. Dargere, J.L. Janneau, V. Paradis, V. Ratziu, F. Charlotte, V. Thibault, F. Imbert-Bismut and T. Poynard, Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C, Aliment Pharmacol Ther 26 (2007), 847-858.
26. A. Suzuki, K. Lindor, J. St Saver, J. Lymp, F. Mendes, A. Muto et al., Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease, J Hepatol 43 (2005), 1060-1066.
27. S.A. Harrison, C. Fincke, D. Helinski, S. Torgerson and P. Hayashi, A pilot study of orlistat treatment in obese, nonalcoholic steatohepatitis patients, Aliment Pharmacol Ther 20 (2004), 623-628.
28. S. Zelber-Sagi, A. Kessler, E. Brazowsky, M. Webb, Y. Lurie, M. Santoet al., A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol 4 (2006), 639-644.
29. S. Abiru, K. Migita, Y. Maeda, M. Daikoku, M. Ito, K. Ohata et al., Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis, Liver Int 26 (2006), 39-45.
30. P. Dandona, R. Weinstock, K. Thusu, E. Abdel-Rahman, A. Aljada and T. Wadden, Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss, J Clin Endocrinol Metab 83 (1998), 2907-2910.
31. G. Lutchman, K. Promrat, D.E. Kleiner, T. Heller, M.G. Ghany, J.A. Yanovski etal., Changesin serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement, Clin Gastroenterol Hepatol 4 (2006), 1048-1052.